Drug intelligence / Profile preview

Nu-8

Development stage: Preclinical
Lead developer: Lakewood-Amedex Biotherapeutics
Modality: Small Molecules
Administration: Inhalation

Overview

**Nu-8** (NU8) is a first-in-class bisphosphocin antimicrobial compound developed by Lakewood-Amedex, featuring a novel chemical structure: 2-(5,6-dimethoxypyridin-3-yl)-1,1-bis(oxidanylidene)-4-[[2,4,6-tris(fluoranyl)phenyl]methyl]pyrido[2,3-e][1,2,4]thiadiazin-3-one. It exhibits broad-spectrum antibacterial activity and is being advanced as an aerosolized direct-to-lung formulation for potential treatment of respiratory infections, including preparation for future pandemics.[3][4][10]

Beyond the preview

Go deeper on Nu-8.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nu-8.

Explore the full profile